Skip to main content
. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501

Figure 2.

Figure 2

The baseline ACC and IR values according to the disease response to nivolumab.Neutrophils (A), lymphocytes (B), platelets (C), NLR (D), SII (E) and PLR (F) were assessed.*Significant differences compared with response (R); ^Significant difference compared with stable disease (S); 2A: p = 0.11 for S vs. R; p = 0.17 for progression (P) vs. R; p = 0.003 for P vs. S; 2B: p = 0.14 for S vs. R; p = 0.018 for P vs. R; p = 0.33 for P vs. S; 2C: p = 0.72 for S vs. R; p = 0.044 for P vs. R; p = 0.036 for P vs. S; 2D: p = 0.61 for S vs. R; p = 0.012 for P vs. R; p = 0.029 for P vs. S; 2E: p = 0.60 for S vs. R; p = 0.003 for P vs. R; p = 0.014 for P vs. S; 2F: p = 0.31 for S vs. R; p = 0.003 for P vs. R; p = 0.032 for P vs. S; p values were adjusted for multiple comparisons using the false discovery rate approach.